Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Retained Earnings (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Retained Earnings for 11 consecutive years, with -$78.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 47.52% to -$78.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$78.2 million through Dec 2025, up 47.52% year-over-year, with the annual reading at -$78.2 million for FY2025, 47.52% up from the prior year.
  • Retained Earnings for Q4 2025 was -$78.2 million at BeOne Medicines, up from -$101.3 million in the prior quarter.
  • The five-year high for Retained Earnings was $17.5 million in Q1 2022, with the low at -$8.6 billion in Q1 2025.
  • Average Retained Earnings over 5 years is -$4.0 billion, with a median of -$4.2 billion recorded in 2021.
  • The sharpest move saw Retained Earnings tumbled 1045353.46% in 2021, then soared 100.5% in 2022.
  • Over 5 years, Retained Earnings stood at -$5.1 billion in 2021, then plummeted by 39.47% to -$7.1 billion in 2022, then surged by 98.6% to -$99.4 million in 2023, then plummeted by 49.82% to -$149.0 million in 2024, then surged by 47.52% to -$78.2 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$78.2 million, -$101.3 million, and -$8.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.